CTOs on the Move

Nutravail Technologies

www.nutravail.com

 
Nutravail Technologies is a Chantilly, VA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.nutravail.com
  • 14790 Flint Lee Rd Ste 100
    Chantilly, VA USA 20151
  • Phone: 703.222.6340

Executives

Name Title Contact Details

Similar Companies

Harmony Business Supplies Inc

Harmony Business Supplies Inc is a Garden Grove, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Eko

Learn how Eko brings together stethoscopes, patient & provider software, and AI-powered analysis—elevating the way we detect and monitor cardiovascular disease.

Windtree Therapeutics

Windtree Therapeutics, Inc. is advancing multiple late-stage interventions for acute cardiovascular and pulmonary disorders to treat patients in moments of crisis. Using new clinical approaches, Windtree is developing a multi-asset franchise anchored around compounds with an ability to activate SERCA2a, with lead candidate istaroxime being developed as a first-in-class treatment for acute heart failure and early cardiogenic shock in heart failure. Windtree has also focused on developing AEROSURF® as a non-invasive surfactant treatment for premature infants with respiratory distress syndrome, and is facilitating transfer of clinical development of AEROSURF® to its licensee in Asia, Lee`s HK, while Windtree evaluates other uses for its synthetic KL4 surfactant for the treatment of acute pulmonary conditions including lung injury due to viral, chemical and radiation induced insults. Also, in its portfolio is rostafuroxin, a novel precision drug product targeting hypertensive patients with certain genetic profiles.

Immune-Tree Inc

Immune-Tree Inc is a Orem, UT-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Esperance Pharmaceuticals

Esperance Pharmaceuticals, Inc. is developing a new class of targeted oncology products that selectively kill cancer cells without harming normal cells. Targeting occurs through binding to specific receptors on the cancer cell surface. The novel product candidates destroy dividing and non-dividing cancer cells including those known to be resistant to chemotherapeutics.